{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:38Z","timestamp":1790109938410,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Prolactinoma account to the most common pituitary adenomas and current therapy regime constitutes of dopamine agonist therapy (DA) and surgery in selected cases [17]. Due to tumor fibrosis induced by previous DA therapy, surgical removal can be challenging though. Therefore, this study investigates how preoperative DA usage influences perioperative treatment and surgical outcome in prolactinoma and aims to ascertain whether a specific subgroup of prolactinoma patients could derive greater benefit from exclusive surgical intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed n\u2009=\u2009159 surgically treated and histologically confirmed prolactinomas in the sella region from 2013\u20132022 in our institution. Clinical, radiological and surgical features were analyzed. Univariate and multivariate analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of total of 159 prolactinoma patients, 83.6% received previous treatment with DA followed by surgery, while only 16.4% received exclusive surgery. Both groups presented similar initial tumor volumes (1.9cm<jats:sup>3<\/jats:sup> vs. 1.5cm<jats:sup>3<\/jats:sup>, p\u2009=\u20090.59) and equal preoperative prolactin levels (PRL) (199.7\u00a0\u00b5g\/l vs. 191.0\u00a0\u00b5g\/l, p\u2009=\u20090.44). Surgical procedures took significantly longer when patients received prior DA treatment (79\u00a0min. vs. 70\u00a0min., p\u2009=\u20090.0479). Six months after surgery, pretreated patients revealed significantly higher PRL compared to non-treated (107\u00a0g\/l vs. 8.64\u00a0\u00b5g\/, p\u2009=\u20090.0009). Additionally, untreated microprolactinoma presented a remission of 100%, whereas pretreated exhibited a remission rate of 88.75%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The current study demonstrates that prior DA treatment is associated with significantly longer surgeries, higher recurrence rates and lower rates of normalization of PRL levels after surgery, particularly in microprolactinomas and support the latest recommendations of the Pituitary Society's Consensus Statement 2023, which favors the option of surgery alone as first-line therapy for microprolactinomas.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00701-024-06198-5","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:08:36Z","timestamp":1722485316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients"],"prefix":"10.1007","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-8838","authenticated-orcid":false,"given":"Alice","family":"Ryba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Gonzalez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rotermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Flitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"1","key":"6198_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33(1):6\u201326","journal-title":"Endocr Pathol"},{"issue":"2","key":"6198_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13(2):220\u2013240","journal-title":"Endocr Rev"},{"issue":"12","key":"6198_CR3","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Li\u00e8ge. Belgium J Clin Endocrinol Metab 91(12):4769\u20134775","journal-title":"Belgium J Clin Endocrinol Metab"},{"issue":"7","key":"6198_CR4","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102\u20132107","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6198_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4158\/EP161446.OR","volume":"23","author":"D Donegan","year":"2017","unstructured":"Donegan D, Atkinson JLD, Jentoft M, Natt N, Nippoldt TB, Erickson B, Meyer F, Erickson D (2017) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23(1):37\u201345","journal-title":"Endocr Pract"},{"issue":"5","key":"6198_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the Treatment of Prolactinomas. Endocr Rev 27(5):485\u2013534","journal-title":"Endocr Rev"},{"key":"6198_CR7","first-page":"11","volume":"65","author":"M Giovanelli","year":"1996","unstructured":"Giovanelli M, Losa M, Mortini P, Acerno S, Giugni E (1996) Surgical results in microadenomas. Acta Neurochir Suppl 65:11\u201312","journal-title":"Acta Neurochir Suppl"},{"key":"6198_CR8","doi-asserted-by":"publisher","DOI":"10.3171\/2011.1.FOCUS10317","author":"CP Hofstetter","year":"2011","unstructured":"Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA, Schwartz TH (2011) Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus. https:\/\/doi.org\/10.3171\/2011.1.FOCUS10317","journal-title":"Neurosurg Focus"},{"issue":"1","key":"6198_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11\u201318","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"6198_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","volume":"58","author":"AM Landolt","year":"1984","unstructured":"Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58(6):1179\u20131183","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6198_CR11","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","volume":"87","author":"M Losa","year":"2002","unstructured":"Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87(7):3180\u20133186","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6198_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci M, Qui\u00f1ones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1):68","journal-title":"Pituitary"},{"issue":"1","key":"6198_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","volume":"46","author":"M Ottenhausen","year":"2023","unstructured":"Ottenhausen M, Conrad J, Wolters LM, Ringel F (2023) Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients. Neurosurg Rev 46(1):128","journal-title":"Neurosurg Rev"},{"issue":"8","key":"6198_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jocn.2008.11.001","volume":"16","author":"CG Patil","year":"2009","unstructured":"Patil CG, Hayden M, Katznelson L, Chang SD (2009) Non-surgical management of hormone-secreting pituitary tumors. J Clin Neurosci 16(8):985\u2013993","journal-title":"J Clin Neurosci"},{"key":"6198_CR15","doi-asserted-by":"crossref","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature Reviews Endocrinology 2023 19:12 19(12):722\u2013740","DOI":"10.1038\/s41574-023-00886-5"},{"issue":"1","key":"6198_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1530\/eje.1.01824","volume":"152","author":"P Petrossians","year":"2005","unstructured":"Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152(1):61\u201366","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"6198_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779\u2013786","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"6198_CR18","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. J Clin Endocrinol Metab 86(11):5256\u20135261","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6198_CR19","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-16-0087","volume":"175","author":"M Tampourlou","year":"2016","unstructured":"Tampourlou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitaki N (2016) THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol 175(3):R89\u2013R96","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"6198_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","volume":"44","author":"JB Tyrrell","year":"1999","unstructured":"Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44(2):254\u2013263","journal-title":"Neurosurgery"},{"key":"6198_CR21","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1016\/j.wneu.2022.12.003","volume":"170","author":"A Uzuner","year":"2023","unstructured":"Uzuner A, Yilmaz E, Caklili M, Selek A, Aydemir F, Cabuk B, Anik I, Ceylan S (2023) Endoscopic Transnasal Approach for Microprolactinomas with Experience of 105 Cases in a Single Center: Paradigmal Shift for Conventional Medical Therapy. World Neurosurg 170:e858\u2013e867","journal-title":"World Neurosurg"},{"issue":"7","key":"6198_CR22","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. J Clin Endocrinol Metab 84(7):2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6198_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167(5):651\u2013662","journal-title":"Eur J Endocrinol"},{"key":"6198_CR24","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","volume":"154","author":"K Wright","year":"2021","unstructured":"Wright K, Chaker L, Pacione D, Sam K, Feelders R, Xia Y, Agrawal N (2021) Determinants of Surgical Remission in Prolactinomas: A Systematic Review and Meta-Analysis. World Neurosurg 154:e349\u2013e369","journal-title":"World Neurosurg"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-024-06198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-024-06198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:02:37Z","timestamp":1740171757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-024-06198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6198"],"URL":"https:\/\/doi.org\/10.1007\/s00701-024-06198-5","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have not received any financial funds, grants or other support whilst preparing this manuscript and likewise that they have no relevant non-financial interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (2023\u2013300417-WF) and performed in accordance the ethical standard of the 1964th Helsinki declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all patients for the publication of anonymized data and findings obtained from this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"316"}}